BiotechTube
Dicerna Pharmaceuticals

Dicerna Pharmaceuticals

DRNA
Lexington, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Overview

Dicerna Pharmaceuticals established itself as a leader in next-generation RNAi therapeutics through its proprietary, liver-targeted GalXC™ and GalXC-Plus™ technology platforms. The company advanced a promising pipeline, most notably nedosiran for primary hyperoxaluria, and forged significant partnerships with industry leaders like Novo Nordisk, Roche, and Eli Lilly. Its successful trajectory culminated in a strategic acquisition by Novo Nordisk in December 2021, integrating Dicerna's platform to expand the acquirer's capabilities in genetic medicine for cardiometabolic and rare diseases.

Rare DiseasesCardiometabolicLiver Diseases

Technology Platform

Proprietary GalXC™ and GalXC-Plus™ RNAi platforms featuring GalNAc-conjugated, chemically stabilized siRNAs designed for subcutaneous, long-duration, liver-targeted gene silencing.

Opportunities

The integration into Novo Nordisk provides immense resources to accelerate the development of Dicerna's RNAi platform for common cardiometabolic diseases, a multi-billion dollar market.
The nedosiran program represents a near-term opportunity to address all types of Primary Hyperoxaluria, an area of high unmet need.
The GalXC-Plus™ platform offers long-term potential to expand therapeutic reach beyond the liver into new disease areas.

Risk Factors

Post-acquisition, key risks include integration challenges within Novo Nordisk and potential deprioritization of non-core programs.
Pipeline assets like nedosiran still face regulatory and commercial execution risks.
The competitive landscape in RNAi therapeutics remains intense, with well-established players like Alnylam.

Competitive Landscape

Dicerna competed directly with RNAi leader Alnylam Pharmaceuticals, particularly in rare liver diseases like primary hyperoxaluria. The broader competitive set included Arrowhead Pharmaceuticals and Silence Therapeutics, along with large pharma companies investing in nucleic acid platforms. Its acquisition by Novo Nordisk transformed it from a competitor into a strategic capability within a larger entity.

More companies in United States →